

REMARKS


Claims 1-13 were rejected under 35 U.S.C. 112, second paragraph, as being indefinite regarding the definition of the methine groups. Applicants have amended claims 1, 5, 8 and 11 to provide that the L groups (methine groups) may be members of a 5- or 6-membered ring, rather than that they may form a 5- or 6-membered ring. Support for this amendment is found at page 5, line 16 of the Application. Compounds of this type are shown in Table 2 at page 12.

Claims 1-4, 6, 8-9 and 12 were rejected under 35 U.S.C. 102(b) as being anticipated by Davis et al. U.S. Patent 6,057,329. The Examiner states that Davis shows a benzothiazine compound, as claimed, as an intermediate. Applicants respectfully traverse this rejection. The compound 3,4-dihydro-3-dimethylaminomethylene-1-methyl-2,2,4-trioxobenzo[c]-2,1-thiazine shown in Example 116 of Davis is the same as 1H-2,1-benzothiazin-4(3H)-one,3-[(dimethylamino)methylene]-1-methyl-,2,2-dioxide shown on the enclosed ACS abstract. This compound is a hemicyanine dye, which is specifically excluded from the definition of D at page 6, line 16 of the Application. Applicants have added this limitation to claim 1.

It is believed that these changes now make the claims clear and definite and, if there are any problems with these changes, Applicants' attorney would appreciate a telephone call.


In light of the above amendments and remarks, Applicants respectfully request that the claims as amended be allowed.

Respectfully submitted,


Sarah Meeks Roberts
Attorney for Applicants
Registration No. 33,447

SMR:fd
Rochester, New York 14650-2201
Phone: (585) 588-7488
Facsimile: (585) 477-1148

209741-66-2



1H-2,1-Benzothiazin-4(3H)-one, 3-[(dimethylamino)methylene]-1-methyl-, 2,2-dioxide (9CI)

~1 Reference

REGISTRY (Copyright 2003 ACS)

Additional Information:

3D Model

Commercial Sources